Search research articles
Contact Us
Filters
Showing results (161-170 of 213) with videos related to
Page
of 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordoma
Gregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients
Santiago Ponce, Miguel Ruiz-Torres, Alejandro Falcón, et al.
Nature Communications
|
April 28, 2022
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma
Emely Möller, Viviane Praz, Sanalkumar Rajendran, et al.
Cell Reports
|
April 16, 2020
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, et al.
Cell Reports
|
April 3, 2020
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability
Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 213) with videos related to
Sort By:
Page
of 22
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordoma
Gregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients
Santiago Ponce, Miguel Ruiz-Torres, Alejandro Falcón, et al.
Nature Communications
|
April 28, 2022
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma
Emely Möller, Viviane Praz, Sanalkumar Rajendran, et al.
Cell Reports
|
April 16, 2020
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, et al.
Cell Reports
|
April 3, 2020
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability
Tugba Keskin, Arnaud Bakaric, Patricia Waszyk, et al.
Page
of 22